D-0501-2017 Class II Terminated

Recalled by G & W Laboratories, Inc. — South Plainfield, NJ

FDA drug recall D-0501-2017 was initiated by G & W Laboratories, Inc. on Feb 7, 2017 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications: Out of specification (OOS) for total impurity and out of trend for known impurity results encountered during stability testing. The recall status is terminated (terminated Jun 18, 2018). Affected quantity: 3456 boxes.

Recall details

Product Type
Drugs
Report Date
Mar 8, 2017
Initiation Date
Feb 7, 2017
Termination Date
Jun 18, 2018
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
3456 boxes

Product description

Indocin (Indomethacin) suppositories, USP, 50 mg, laminate strips packed in boxes of 30, Rx only, Manufactured by: G&W Laboratories Inc. South Plainfield, NJ 07080, Distributed by Iroko Pharmaceuticals, LLC Philadelphia, PA 19112, NDC 42211-0102-43

Reason for recall

Failed Impurities/Degradation Specifications: Out of specification (OOS) for total impurity and out of trend for known impurity results encountered during stability testing.

Distribution pattern

Within United States

Code information

Lot #: 017600011, Exp. Jan 2018, 0176000014, Exp. Aug 2018, 017600015, Exp. Sep 2018

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0501-2017
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0501-2017. Report a data issue: hello@regdatalab.com.